Recent advancements in glucose dysregulation and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT): an update of ICET-A (International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescence Medicine)
Glucose disorders and osteoporosis in thalassemia
Keywords:
Transfusion-dependent thalassemia, short stature, growth and endocrine disorders, risk factors, osteoporosis.Abstract
Purpose of review: The aim of this short review is to provide an update on glucose homeostasis, insulin secretion and pharmacological management of osteoporosis in transfusion-dependent thalassemia (TDT). Recent findings: A retrospective study, documenting the changes in glucose-insulin homeostasis from early childhood to young adulthood, has advanced our understanding of the evolution of glucose regulation in patients with TDT. Magnetic Resonance Imaging (T2* MRI) is considered to be a reliable tool to measure pancreatic iron overload. Continuous glucose monitoring systems (CGMS) can be used in early diagnosis of glucose dysregulation and in disease management in patients with already diagnosed diabetes. Oral glucose-lowering agents (GLAs) are effective and safe for the treatment of diabetes mellitus (DM) in patients with TDT, achieving adequate glycemic control for a substantial period of time. Current modalities for the management of osteoporosis in adults with TDT include inhibitors of bone remodeling such as bisphosphonates and denosumab as well as stimulators of bone formation (e.g., teriparatide), Considering the unique characteristics of osteoporosis associated with TDT, early diagnosis, treatment initiation and treatment duration are critical issues in the management this special population. Conclusions: Advances in the care of TDT patients have led to improved survival and quality of life. Nevertheless, many chronic endocrine complications still remain. Their routine screening and a high index of suspicion are imperative in order to provide timely diagnosis and treatment.
References
Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassemia.Lancet.2022;399(10343):2310-24.doi:10.1016/ S0140-6736(22)00536-0.
De Sanctis V, Soliman A, Tzoulis P, et al. The prevalence of glucose dysregulations (GDs) in patients with β-thalassemias in different countries: A preliminary ICET-A survey. Acta Biomed. 2021; 92(3): e2021240. doi: 10.23750/abm.v92i3.11733.
Ibrahim AS, Abd El-Fatah AH, Abd El-Halim AF, Mohamed FF. Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major. J Blood Med. 2023;14: 67-81. doi: 10.2147/JBM.S390666.
De Sanctis V, Soliman A, Daar S, et al. Insulin-Like Growth Factor -1 (IGF-1) and Glucose Dysregulation in Young Adult Patients with β-Thalassemia Major: Causality or Potential Link? Acta Biomed. 2022; 93(6): e2022331. doi: 10.23750/abm.v93i6.13288.
De Sanctis V, Soliman A, Tzoulis P, et al. The clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent β-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM). Acta Biomed. 2022; 92(6): e2021488. doi:10. 23750/ abm. v92i6.12366.
Meloni A, De Marchi D, Pistoia L, Grassedonio E, et al. A Multicenter validation of the magnetic resonance T2* technique for quantification of pancreatic iron. Eur Radiol. 2019; 29(5):2246-52. doi: 10.1007/s00330-018-5783-6.
Wahidiyat PA, Iskandar SD, Sekarsari D. Evaluation of Iron Overload Between Age Groups Using Magnetic Resonance Imaging and Its Correlation with Iron Profile in Transfusion-dependent Thalassemia. Acta Med Indones. 2018; 50(3):230-6.
Pepe A, Pistoia L,Gamberini MR, et al. The Close Link of Pancreatic Iron with Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study. Diabetes Care. 2020;43(11):2830-9. doi: 10.2337/dc20-0908.
Farmakis D, Porter J, Taher A, Cappellini MD, Angastiniotis M, Eleftheriou A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022;6(8):e732. doi: 10.1097/HS9.0000000000000732.
Huang J, Shen J, Yang Q, Cheng Z, et al. Quantification of pancreatic iron overload and fat infiltration and their correlation with glucose disturbance in pediatric thalassemia major patients. Quant Imaging Med Surg. 2021;11(2):665-75. doi: 10.21037/qims-20-292.
Hashemieh M, Radfar M, Azarkeivan A, et al. T2* Magnetic Resonance Imaging Study of Pancreatic Iron Overload and its Relation With the Diabetic State in Thalassemic Patients. J Pediatr Hematol Oncol. 2017;39 (5):337-40. doi: 10.1097/MPH.0000000000000767.
Sevimli C, Yilmaz Y, Bayramoglu Z, et al. Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience. Clin Exp Med. 2022;22(1):95-101. doi: 10.1007/s10238-021-00735-7.
Karadas N, Yurekli B, Bayraktaroglu S, Aydinok Y. Insulin secretion-sensitivity index-2 could be a novel marker in the identification of the role of pancreatic iron deposition on beta-cell function in thalassemia major. Endocr J. 2019;66(12):1093-9. doi: 10.1507/endocrj.EJ19-0191.
Carsote M, Vasiliu C, Trandafir AI, et al. New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement. Diagnostics (Basel). 2022;12(8):1921.doi: 10.3390/ diagnostics 12081921.
Meloni A, Pistoia L, Ricchi P, et al. Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia. J Pers Med. 2022;12(3):400. doi: 10.3390/jpm12030400.
De Sanctis V, Daar S, Soliman AT, et al. Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience. Acta Biomed 2022; 93(1): e2022158. doi: 10. 23750/abm.v93i1.12802.
Choudhary A, Giardina P, Antal Z, Vogiatzi M. Unreliable oral glucose tolerance test and haemoglobin A1C in beta thalassaemia major-a case for continuous glucose monitoring? Br J Haematol. 2013 Jul;162(1):132-5. doi: 10.1111/bjh.12322.
De Sanctis V, Daar S, Soliman AT, et al. Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience. Acta Biomed. 2022 Mar 14;93(1):e2022158. doi: 10.23750/abm.v93i1.12802.
Soliman A, De Sanctis V, Yassin M, Elalaily R. Therapeutic Use and Diagnostic Potential of Continuous Glucose Monitoring Systems (CGMS) in Adolescents. Adv Diab Metab. 2014;2:21-30. doi: 10.13189/ adm. 2014.020201.
Soliman A, De Sanctis V, Yassin M, et al. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab. 2014;18(3):274-82. doi: 10.4103/ 2230-8210.131130.
De Sanctis V, Soliman AT, Elsedfy H, et al. Diabetes and Glucose Metabolism in Thalassemia Major: An Update. Expert Rev Hematol. 2016;9(4):401-8. doi: 10.1586/17474086.2016.1136209.
De Sanctis V, Soliman AT, Elsedfy H, et al. The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients. Mediterr J Hematol Infect Dis. 2016;8(1):e2016058. doi: 10.4084/MJHID.2016.058.
El-Samahy MH, Tantawy AA, Adly AA, et al. Evaluation of continuous glucose monitoring system for detection of alterations in glucose homeostasis in pediatric patients with β-thalassemia major. Pediatr Diabetes. 2019;20(1):65-72. doi:10.1111/pedi.12793.
Soliman AT, Yassin M, El-Awwa A, De Sanctis V. Detection of glycemic abnormalities in adolescents with beta thalassemia using continuous glucose monitoring and oral glucose tolerance in adolescents and young adults with β-thalassemia major: Pilot study. Indian J Endocrinol Metab.2013;17(3):490-5.doi:10.4103/2230-8210.111647.
De Sanctis V, Daar S, Soliman AT, Tzoulis P, Karimi M, Kattamis C. Evolution of glucose-insulin homeostasis in children with β-thalassemia major (β-TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthood. Acta Biomed. 2022; 93(3): e2022243. doi: 10.23750/abm.v93i3.12643.
De Sanctis V, Soliman A, Tzoulis P, Daar S, Pozzobon GC, Kattamis C. A study of isolated hyperglycemia (blood glucose ≥155 mg/dL) at 1-hour of oral glucose tolerance test (OGTT) in patients with β -transfusion dependent thalassemia (β-TDT) followed for 12 years. Acta Biomed. 2021; 92(4): e2021322. doi:10.23750/abm.v92i4.11105.
De Sanctis V, Daar S, Soliman AT, Tzoulis P, Yassin MA, Kattamis C. Evolution of Combined Impaired Fasting Glucose and Impaired Glucose Tolerance in β-Thalassemia Major: Results in 58 Patients with a Mean 7.7- year Follow-Up. Acta Biomed. 2022; 93(3): e2022242. doi:10.23750/abm.v93i3.12825.
De Sanctis V, Soliman AT, Daar S, Tzoulis P, Di Maio S, Kattamis C. Longitudinal study of ICET-A on glucose tolerance, insulin sensitivity and β-cell secretion in eleven β-thalassemia major patients with mild iron overload. Acta Biomed. 2023; 94(1): e2023011. doi:10.23750/abm.v94i1.14000.
De Sanctis V, Soliman AT, Daar S, Tzoulis P, Di Maio S, Kattamis C. Glucose Homeostasis and Assessment of β-Cell Function by 3-hour Oral Glucose Tolerance (OGTT) in Patients with β-Thalassemia Major with Serum Ferritin below 1,000 ng/dL: Results from a Single ICET-A Centre. Mediterr J Hematol Infect Dis 2023; 15(1): e2023006. doi: 10.4084/MJHID.2023.006.
Meloni A, Pistoia L, Ricchi P, et al. Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy. Blood Adv.2022- 008805. doi:10.1182/ bloodadvances. 2022008805.
De Sanctis V, Soliman A, Tzoulis P, et al. The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network. Acta Biomed. 2022; 93(2): e2022162. doi: 10.23750/abm.v93i2.12056.
Fung EB, Ahmad T, Killilea DW, Hussain R, Lal A. Zinc supplementation improves markers of glucose homeostasis in thalassaemia. Br J Haematol. 2020; 190(3): e162-e6. doi: 10.3390/nu7064296.
Matter RM, Elbarbary NS, Ismail EAR, Darwish YW, Nada AS, Banoub VP. Zinc supplementation improves glucose homeostasis in patients with β-thalassemia major complicated with diabetes mellitus: A randomized controlled trial. Nutrition. 2020;73:110702. doi.org/10.1016/j.nut.2019.110702.
De Sanctis V, Soliman AT, Elsefdy H, et al . Bone disease in beta thalassemia patients: past, present and future perspectives. Metabolism. 2018;80:66-79. doi: 10.1016/j.metabol.2017.09.012.
Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002;13(8):644-9. doi: 10.1007/s001980200087.
Gilfillan CP, Strauss BJ, Rodda CP, et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int. 2006;79(3):138-44. doi: 10.1007/s00223-006-0314-x.
Voskaridou E, Anagnostopoulos A, Konstantopoulos K, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006;91(9):1193-1202.PIMD:16956818.
Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica. 2008;93(10):1588-90. doi: 10.3324/haematol.12849.
Giusti A. Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab. 2014;32(6):606-15. doi: 10.1007/s00774-014-0584-8.
Reid IR, Horne AM, Mihov B, et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018;379(25):2407-2416. doi: 10.1056/NEJMoa1808082.
Stathopoulos IP, Liakou CG, Katsalira A, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10(4):280-91. doi: 10.14310/horm.2002.1319.
Chatterjee R, Bajoria R, Shah FT, Porter JB, Fedele S. High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major. Br J Haematol. 2014;166(2):292-4. doi: 10.1111/bjh.12833
Lampropoulou-Adamidou K, Tournis S, Triantafyllopoulos IK. Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. J Musculoskelet Neuronal Interact. 2016;16(1):75-8.PIMD:26944826.
Leung TY, Lao TT. Thalassaemia in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2012;26(1):37-51. doi: 10.1016/j.bpobgyn.2011.10.009.
Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO, Aziz Bedair EM, Abdel Gawad M. Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis. Indian J Endocrinol Metab. 2014;18(4):546-51. doi: 10.4103/2230-8210.137516.
Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, et al. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018;2(21):2837-47. doi: 10.1182/bloodadvances.2018023085.
Makras P, Appelman-Dijkstra NM, Papapoulos SE, et al. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. J Clin Endocrinol Metab. 2021;106(10):e4155-e62. doi: 10.1210/clinem/dgab321.
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020. dgaa756. doi: 10.1210/clinem/dgaa756.
Gagliardi I, Celico M, Gamberini MR, et al. Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience. Calcif Tissue Int. 2022;111(1):56-65. doi: 10.1007/s00223-022-00963-3.
Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009;24(4):726-36. doi: 10.1359/jbmr.081215.
Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015; 386 (9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5.
Shane E, Shiau S, Recker RR, et al. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2022;107(4):e1528-e40. doi: 10.1210/clinem/dgab850.
Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):503-11. doi: 10.1002/jbmr.238.
Charoenngam N , Rittiphairoj T, Ponvilawan, B. Fracture prevalence in thalassemia: a systematic review and meta-analysis. Arch Osteoporos.2021;16:171. doi.org/10.1007/s11657-021-01026-0.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ploutarchos Tzoulis , Maria P. Yavropoulou, Atanas Banchev, Iskra Modeva, Shahina Daar, Vincenzo De Sanctis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
